zika
viru
zikv
infect
caus
congenit
malform
includ
microcephali
infant
caus
disord
syndrom
meningoenceph
myeliti
also
occur
infect
adult
howev
time
drug
approv
treat
zikv
infect
drug
repurpos
promptest
way
obtain
effect
drug
global
public
health
emerg
spread
zika
viru
studi
report
us
food
drug
admistrationapprov
drug
safe
pediatr
use
nitazoxanid
bioactiv
metabolit
tizoxanid
antizikv
potenti
vitro
identifi
exert
antivir
effect
possibl
target
viral
postattach
step
zika
viru
zikv
mosquitoborn
flaviviru
first
isol
uganda
positivestrand
ribonucl
acid
rna
genom
approxim
nucleotid
zika
viru
transmit
aed
spp
mosquito
also
sexual
contact
blood
transfus
urin
saliva
vertic
mother
fetu
sinc
larg
zika
outbreak
happen
brazil
zikv
transmiss
report
countri
region
global
although
patient
infect
zikv
asymptomat
lead
fetal
microcephali
pregnant
women
may
increas
risk
neurolog
disord
myeliti
infect
adult
associ
zikv
infect
testi
damag
prove
mous
model
recent
aris
concern
zikv
infect
infertil
male
protect
public
health
especi
avoid
birth
defect
necessari
find
safe
drug
taken
mouth
oral
prophylact
therapeut
use
epidem
advantag
drug
repurpos
compar
de
novo
drug
develop
public
emerg
rapid
clinic
applic
repurpos
drug
base
idea
xu
et
al
perform
drug
repurpos
screen
report
us
food
drug
admistr
fda
approv
pregnanc
categori
b
anthelmint
drug
call
niclosamid
show
antizikv
effect
vitro
barrow
et
al
also
screen
fdaapprov
drug
librari
report
seri
fdaapprov
drug
capabl
inhibit
zikv
vitro
eyer
et
al
identifi
nucleosid
inhibitor
inhibit
zikv
replic
cell
cultur
howev
research
need
conduct
abovement
antivir
clinic
appli
studi
report
pediatr
drug
nitazoxanid
broadspectrum
antivir
agent
initi
approv
fda
antiprotozoan
drug
overwhelm
safeti
due
extens
postmarket
experi
involv
almost
million
adult
children
potenti
inhibit
zikv
infect
vitro
identifi
target
postvir
entri
step
exert
antivir
effect
vero
cell
vero
cell
cell
maintain
co
dulbecco
minimum
essenti
medium
dmem
supplement
fetal
bovin
serum
fb
penicillinstreptomycin
unitsml
respect
zika
viru
strain
genbank
number
obtain
center
emerg
infecti
diseas
wuhan
institut
virolog
chines
academi
scienc
wuhan
china
viru
stock
propag
vero
cell
viru
stock
titrat
plaqueform
unit
pfu
vero
cell
ribonucl
acid
extract
use
qiaamp
viral
rna
mini
kit
qiagen
hilden
germani
follow
manufactur
protocol
complementari
deoxyribonucl
acid
cdna
synthes
use
revertra
ace
qpcr
rt
kit
toyobo
osaka
japan
ribonucl
acid
quantifi
use
realtim
polymeras
chain
reaction
pcr
appli
biosystem
realtim
pcr
system
realtim
pcr
perform
use
cdna
specif
primer
target
gene
interest
forward
agtgtgacgtggacatccgcaaag
revers
atccacatctgctggaaggtggac
zikv
forward
caactactgcaagtggaagggt
revers
aagtggtccatatgatcggttga
quantit
pcr
sybr
green
realtim
pcr
master
mix
toyobo
final
reaction
volum
cycl
condit
cycl
second
second
second
messeng
rna
mrna
express
fold
induct
quantifi
calcul
valu
mrna
endogen
control
variou
concentr
compound
ad
vero
cell
day
cell
viabil
determin
use
celltiterglo
luminesc
cell
viabil
kit
promega
madison
wi
accord
manufactur
instruct
infect
cell
fix
paraformaldehyd
phosphatebuff
salin
pb
hour
room
temperatur
treat
triton
fetal
calf
serum
minut
cell
incub
hour
monoclon
antibodi
flaviviru
envelop
protein
clone
mous
millipor
billerica
follow
incub
alexa
fluor
secondari
antibodi
dye
use
stain
nucleu
stain
cell
analyz
fluoresc
microscopi
serial
dilut
zikv
inocul
vero
cell
seed
plate
hour
remov
cell
overlay
ml
fb
dmem
contain
carboxymethyl
cellulos
sodium
salt
cmc
cultur
hour
cmc
overlay
remov
cell
fix
formaldehyd
half
hour
stain
crystal
violet
ethanol
plaqu
count
express
pfu
per
mllilit
pfu
ml
vero
cell
lyse
ice
radioimmunoprecipit
assay
ripa
buffer
complet
proteas
inhibitor
cocktail
tablet
roch
diagnost
gmbh
mannheim
germani
protein
mix
load
buffer
subject
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
electrotransf
onto
polyvinyliden
fluorid
pvdf
membran
millipor
membran
block
tween
contain
skim
milk
incub
overnight
homemad
antizikv
capsid
polyclon
antibodi
capsid
peptid
sequenc
design
mknpkkksggfrivc
sigma
darmstadt
germani
membran
wash
time
pbstween
subsequ
incub
room
temperatur
hour
secondari
antibodi
pbstween
contain
skim
milk
signal
analyz
chemiluminesc
use
imagequ
ge
healthcar
bioscienc
pittsburgh
pa
zika
viru
nitazoxanid
tizoxanid
bound
vero
cell
hour
wash
time
pb
zikv
rna
level
determin
quantit
rtpcr
qrtpcr
immedi
bind
zika
viru
nitazoxanid
tizoxanid
incub
hour
wash
time
pb
chang
fb
dmem
hour
later
cell
harvest
zikv
rna
detect
qrtpcr
assay
pediatr
clinic
drug
nitazoxanid
bioactiv
metabolit
tizoxanid
test
serial
concentr
abil
inhibit
zikv
prolifer
vero
cell
plaqu
assay
supplementari
figur
shown
figur
drug
inhibit
viru
titer
dosedepend
manner
nitazoxanid
reduc
infecti
zikv
particl
wherea
tizoxanid
complet
abolish
supernat
zikv
prolifer
inhibit
demonstr
immunofluoresc
assay
detect
envelop
protein
express
figur
western
bot
detect
zikv
capsid
protein
figur
cytotox
observ
drug
assay
concentr
figur
investig
kinet
zikv
propag
presenc
drug
supplementari
figur
obviou
inhibit
observ
addit
drug
inhibit
intracellular
zikv
rna
product
dosedepend
manner
differ
multipl
infect
moi
supplementari
figur
verifi
whether
nitazoxanid
tizoxanid
could
inhibit
zikv
humanderiv
cell
perform
antivir
experi
cell
found
drug
could
inhibit
zikv
infect
dosedepend
manner
nontox
dose
figur
toxic
data
shown
explor
antivir
mechan
drug
first
investig
whether
affect
viral
attach
stage
treat
vero
cell
drug
zikv
figur
viral
particl
physic
bind
cell
surfac
without
endocytosi
occur
effici
wash
remov
unadsorb
zikv
cell
harvest
zikv
rna
detect
result
show
drug
inhibit
attach
zikv
cell
demonstr
result
perform
similar
experi
vero
cell
cotreat
zikv
drug
hour
remov
virusdrug
pb
wash
cell
incub
fresh
medium
without
drug
allow
subsequ
infect
occur
zikv
rna
determin
hour
later
figur
consist
result
figur
drug
inhibit
zikv
infect
suggest
nitazoxanid
tizoxanid
inhibit
attach
zikv
cell
determin
step
drug
may
inhibit
zikv
infect
perform
timeofdrugaddit
assay
ad
drug
zikv
inocul
vero
cell
figur
result
indic
ad
drug
hour
postinfect
also
exert
antizikv
effect
effici
compar
cotreat
suggest
drug
inhibit
viru
infect
viru
attach
pretreat
cell
compound
hour
inhibit
zikv
infect
confirm
compound
act
zikv
entri
supplementari
figur
addit
perform
timeofaddit
experi
use
high
moi
shown
figur
addit
compound
hour
zikv
infect
moi
still
potent
inhibit
viru
infect
strongli
suggest
drug
capabl
inhibit
establish
zikv
infect
like
step
viru
genom
replic
also
report
inhibit
replic
broad
rang
rna
dna
virus
includ
respiratori
syncyti
viru
parainfluenza
coronaviru
rotaviru
noroviru
hepat
b
hepat
c
dengu
yellow
fever
japanes
enceph
viru
human
immunodefici
viru
clinic
trial
indic
potenti
role
treat
rotaviru
noroviru
gastroenter
chronic
hepat
b
chronic
hepat
c
influenza
suggest
nitazoxanid
may
inhibit
viru
infect
regul
host
respons
specif
mechan
may
associ
deplet
intracellular
ca
store
thiazolid
also
report
inhibit
replic
differ
strain
influenza
viru
select
block
matur
viral
hemagglutinin
stage
preced
resist
endoglycosidas
h
digest
result
indic
nitazoxanid
inhibit
zikv
infect
target
postattach
step
like
viru
genom
replic
perhap
also
inhibit
zikv
replic
deplet
intracellular
ca
store
like
bovin
viral
diarrhoea
viru
howev
novel
mechan
exclud
set
investig
need
perform
zikv
infect
asymptomat
howev
associ
congenit
brain
defect
neurolog
disord
infertil
male
make
global
public
health
emerg
thu
propos
emerg
prophylact
drug
use
consid
ideal
repurpos
antizikv
drug
meet
follow
criteria
prophylact
use
class
b
fda
pregnanc
categori
oral
administ
rel
high
c
max
compar
vitro
efficaci
concentr
oral
administr
current
avail
dosag
form
ensur
effect
plasma
drug
exposur
low
permeabl
imperm
across
placent
barrier
categori
b
drug
ensur
safeti
fetu
luckili
nitazoxanid
might
uniqu
drug
meet
criteria
date
oral
taken
pregnanc
categori
b
drug
approv
adult
children
c
max
plasma
tizoxanid
tizoxanid
glucuronid
respect
oral
administr
tablet
much
higher
concentr
requir
complet
clear
viru
vitro
tizoxanid
cytotox
vero
cell
observ
drug
figur
vitro
antizikv
activ
nitazoxanid
seem
high
recent
report
niclosamid
howev
niclosamid
margin
absorb
blood
stream
oral
administr
consider
multidisciplinari
factor
nitazoxanid
may
better
antizikv
drug
worth
immedi
clinic
research
supplementari
materi
avail
open
forum
infecti
diseas
onlin
consist
data
provid
author
benefit
reader
post
materi
copyedit
sole
respons
author
question
comment
address
correspond
author
